GUARDANT
INFINITY™

Exceptional technology. **Extraordinary potential.**

Introducing **Guardant Infinity – the first and only commercial platform** that combines **epigenomic and genomic profiling** via liquid biopsy to offer a truly multidimensional view of cancer.[1]

Precision oncology has advanced our ability to match the right patient to the right treatment at the right time – but we are just getting started.

A NEW DIMENSION OF INSIGHTS: AN EPIGENOMIC EXAMPLE



Genomic profiling offers details into alterations of the genomic DNA…

…while **epigenomic profiling** can help detect alterations to the *expression* of the genome.

The epigenome is a dynamic landscape providing breakthrough insights to offer a more complete view of cancer[2-5]

A growing body of evidence demonstrates that **epigenetic changes have a tremendous impact on cancer development and progression**.[6,7]

Epigenomic insights, specifically methylation sequencing, can advance multiple precision oncology applications.

IDENTIFY MORE PATIENTS



Dramatically improve sensitivity in MRD and monitoring & potentially **identify up to 50% more cancer patients*** [1,8,9]

BETTER PREDICT RESPONSE TO TREATMENT

Potentially identify subsets of patients eligible for specific therapies, **predict response to therapy and survival probability**[10–12]

STRATIFY PATIENTS AND CANCERS



Discriminate between cancer subtypes, allowing for more precise treatment selection[12]

*compared to genomic-only detection

In a clinical setting, Guardant products powered by the Infinity platform can have:

Even faster turnaround times post- sample receipt[13]

Enhanced sensitivity, with 100x to 1000x more signals available to analyze[1]



New insights across the continuum of care, from MRD to progression

Guardant Infinity will soon power our Treatment Selection & Monitoring portfolio of products.

The next era of precision oncology is here. See what's next, now, with Guardant Infinity.

References:

1. GuardantINFINITY™: Specifications Sheet. Guardant Health, Inc. Redwood City, CA. January 4, 2023
2. Watts, G.S., Futscher, B.W., Holtan, N. et al. DNA methylation changes in ovarian cancer are cumulative with disease progression and identify tumor stage. BMC Med Genomics 1, 47 (2008). https://doi.org/10.1186/1755-8794-1-47
3. Muthamilselvan, Sangeetha, Abirami Raghavendran, and Ashok Palaniappan. "Stage-differentiated ensemble modeling of DNA methylation landscapes uncovers salient biomarkers and prognostic signatures in colorectal cancer progression." Plos one 17.2 (2022): e0249151.
4. Klajic, J., Fleischer, T., Dejeux, E. et al. Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumors. BMC Cancer 13, 456 (2013). https://doi.org/10.1186/1471-2407-13-456
5. Oue, Naohide, et al. "Accumulation of DNA methylation is associated with tumor stage in gastric cancer." Cancer: Interdisciplinary International Journal of the American Cancer Society 106.6 (2006): 1250-1259.
6. Yoshimi A, Lin KT, Wiseman DH, et al. Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis. *Nature*. 2019;574(7777):273-277. doi:10.1038/s41586-019-1618-0
7. Teixeira VH, Pipinikas CP, Pennycuick A, et al. Deciphering the genomic, epigenomic, and transcriptomic landscapes of pre-invasive lung cancer lesions. *Nat Med*. 2019;25(3):517-525. doi:10.1038/s41591-018-0323-0
8. Greenwald WY, He Y, Chen S, et al. Accurate epigenomic estimates of circulating tumor fraction in large-scale clinical data. Poster presented at: American Association for Cancer Research Annual Meeting; April 8-13, 2022; Philadelphia, PA. Accessed April 12, 2023.
9. Guardant Health data on file: Guardant360 Response™. Guardant Health, Inc. Redwood City, CA.
10. Yen J. BRCA1 promoter methylation in sporadic breast cancer patients detected by liquid biopsy. Poster presented at: American Association for Cancer Research Annual Meeting. April 14-19, 2023: Orlando, FL.
11. Kondrashova O, Topp M, Nesic K, et al. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. *Nat Commun*. 2018:3970(9). https://doi.org/10.1038/s41467-018-05564-z
12. Berchuck JE, Baca SC, McClure HM, et al. Detecting neuroendocrine prostate cancer through tissue-informed cell-free DNA methylation analysis. *Clin Cancer Res*. 2022:28(5):928–938. doi:10.1158/1078-0432.CCR-21-3762
13. Guardant Health data on file: Guardant Infinity Platform. Guardant Health, Inc. Redwood City, CA.

MKT-000269 R1

GUARDANT™

GUARDANT INFINITY™